STOCK TITAN

ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

ESSA Pharma Inc. (NASDAQ: EPIX) announced its participation in a fireside chat at the Guggenheim Healthcare Talks 5th Annual Oncology Conference on February 9, 2023, at 9:00 a.m. Eastern Time in New York City. Key executives, including President and CEO David R. Parkinson, will also hold one-on-one meetings. A live webcast of the presentation will be available on ESSA's website, with an archived replay accessible for 30 days after the event. ESSA focuses on developing novel therapies for prostate cancer, aiming to provide innovative treatment solutions for patients.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 2, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will participate in a fireside chat at the Guggenheim Healthcare Talks 5th Annual Oncology Conference in New York City on Thursday, February 9, 2023, at 9:00 a.m. Eastern Time.

David R. Parkinson, President and Chief Executive Officer of ESSA Pharma; Peter Virsik, ESSA's Chief Operating Officer; and David S. Wood, ESSA's Chief Financial Officer, will host and participate in one-on-one meetings.

A live webcast of the presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. An archived replay of the event will be available for 30 days.

About ESSA Pharma Inc.

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.

Cision View original content:https://www.prnewswire.com/news-releases/essa-pharma-to-participate-in-the-guggenheim-healthcare-talks-5th-annual-oncology-conference-301737785.html

SOURCE ESSA Pharma Inc

FAQ

What is ESSA Pharma's participation in the Guggenheim Healthcare Talks 5th Annual Oncology Conference?

ESSA Pharma will participate in a fireside chat at the conference on February 9, 2023, at 9:00 a.m. Eastern Time in New York City.

Who are the key executives representing ESSA Pharma at the conference?

Key executives include David R. Parkinson, President and CEO; Peter Virsik, Chief Operating Officer; and David S. Wood, Chief Financial Officer.

Where can I access the live webcast of ESSA Pharma's presentation?

The live webcast can be accessed on ESSA Pharma's website in the Investors/Events & Presentations section.

How long will the archived replay of ESSA Pharma's conference presentation be available?

The archived replay will be available for 30 days after the event.

What is the focus of ESSA Pharma's research and development?

ESSA Pharma focuses on developing novel and proprietary therapies for the treatment of prostate cancer.

ESSA Pharma Inc.

NASDAQ:EPIX

EPIX Rankings

EPIX Latest News

EPIX Stock Data

77.01M
43.38M
2.26%
81.19%
2.59%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
VANCOUVER